BioCardia Inc
NASDAQ:BCDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
GK Software SE
XETRA:GKS
|
DE |
|
H
|
Hoku Corp
OTC:HOKUQ
|
US |
BioCardia Inc
Tax Provision
BioCardia Inc
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BioCardia Inc
NASDAQ:BCDA
|
Tax Provision
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Tax Provision
-$2.4B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-5%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Tax Provision
-$1.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Tax Provision
-$1.3B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Tax Provision
-$690m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-37%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Tax Provision
-$681.3m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-1%
|
|
BioCardia Inc
Glance View
BioCardia, Inc. operates as a clinical-stage regenerative medicine company. The company is headquartered in Sunnyvale, California and currently employs 28 full-time employees. The company is focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. Its lead therapeutic candidates are based on the CardiAMP Cell Therapy System, a platform which provides an autologous bone marrow-derived cell therapy for treatment in two clinical indications, such as ischemic heart failure and refractory angina resulting from chronic myocardial ischemia. Its second therapeutic platform is an investigational bone marrow derived allogeneic off-the shelf Neurokinin-1 Receptor Positive mesenchymal stem cell (MSC) therapy for the treatment of cardiac and pulmonary disease. The company has three enabling device product lines: the CardiAMP cell processing system, the Helix biotherapeutic delivery system (Helix), and the Morph vascular access product line (Morph). The company is advancing therapeutic candidates for heart failure, chronic myocardial infarction, and acute respiratory distress syndrome.
